Drug Manufacturer/Opioid	FDA Approval Status	Where Is It Now?
Pfizer's Embeda (morphine/naltrexone)	August 2009; updated with AD-claims in 2014	Marketed, but Pfizer does not break out sales; $61.1m in 2016 US sales reported by IQVIA
Purdue's Oxycontin (oxycodone)	2010; reformulated with AD properties and approved with claims in April 2013	Marketed; a blockbuster and one of the most commercially successful AD opioids but Purdue does not report financials
Egalet'sOxaydo (oxycodone)	June 2011; launch delayed until Sept. 2015; formulated to deter intranasal abuse; no labeling claim	Marketed; Egalet announced combined Oxaydo, Aramyo and Sprix sales of $26.1m in 2016
Endo'sOpana ER (oxymorphone)	Crush-resistant formulation launched in 2012, though FDA never approved AD claims	No longer marketed; withdrawn from the market in 2017 at request of FDA because of intravenous abuse concerns
Collegium'sNucynta ER (tapentadol)	Approved in August 2011 and launched by Janssen, designed with AD properties but no claims; DepoMed acquired rights from Janssen in 2015 for $1.05bn in cash	Nucynta products generated $239.5m in 2017; DepoMed has decided to stop making opioids and gave commercial rights to Collegium in a 2018 deal for $10m in cash and a minimum $135m annual payment for four years
Pernix'sZohydro ER (hydrocodone)	Reformulated with AD properties in Feb. 2015 after initial approval was deemed controversial; no FDA-approved AD claims	Originator Zogenix off-loaded Zohydro ER to Pernix in 2015 for $100m plus cash; it generated $18m in first nine months of 2017
Mallinckrodt'sXartemis XR (oxycodone/acetaminophen)	Approved in 2014 formulated with AD properties, but not with AD claims	Discontinued in mid-2017
Purdue'sTarginiq ER (oxycodone/naloxone)	Approved in 2014 as the second opioid with AD claims	Never launched; Purdue says it continues to monitor market conditions
Purdue'sHysingla ER (hydrocodone)	Third opioid approved by FDA with AD claims in November 2014	On the market; Purdue does not break out sales
Biodelivery Sciences'Belbuca (buprenorphine)	Endo secured FDA approval for Belbuca in 2015, but without abuse deterrent claims	Endo returned rights to Belbuca to BDSI and took a $40m impairment charge; generated $17.6m in first nine months of 2017
Daiichi-Sankyo/Inspirion's MorphaBond ER (morphine)	Approved in October 2015 with AD claims	Daiichi signed on as a commercial partner in 2016 and MorphaBond launched in November 2017
Pfizer'sTroxyca ER (oxycodone/naltrexone extended-release)	Approved in August 2016 with AD claims	Pfizer hasn't launched Troxyca and would not comment on commercial plans.
Teva'sVantrela ER (hydrocodone extended-release)	Approved January 2017 with AD claims	Teva has not launched Vantrela and said it has no plans to at this time
Daiichi-Sankyo/Inspirion'sRoxybond (oxycodone immediate-release)	Approved in April 2017 with AD claims	Daiichi-Sankyo plans to commercialize
Collegium's Xtampza ER (oxycodone)	Approved in April 2016, with AD claims	Xtampza ER generated sales of $28.5m in 2017
Egalet's Arymo ER (morphine)	Approved in January 2017 but tentative approval for a new AD claim was in December 2017, pending patent exclusivity issue set to expire in October	Marketed; Egalet announced combined Oxaydo, Aramyo and Sprix sales of $16.9m in 2016
KemPharm's Apadaz (benzhydrocodone/acetaminophen)	Approved February 2018 with AD properties, but no claims	KemPharm said it is seeking a generic partner and plans to launch at generic pricing
Pain Therapeutics' Remoxy (oxycodone extended-release)	Pending at FDA with Aug. 7 action date	Pfizer once owned rights but after two rejections by FDA it returned rights to Pain in 2014; Pain got a third FDA rejection in 2016 but resubmitted in February 2018

Abuse-Deterrent Opioids: Where Are They Now?

More from Drug Pricing

More from Scrip